Lexaria Bioscience (LEXX) FCF Margin Growth (1y) (2018 - 2026)
Lexaria Bioscience (LEXX) FCF Margin Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -89.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1,183.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 26,102.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 869.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 769.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 4,109.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 19,111.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.00 |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -1.02 Mn |
| Aug 31, 2025 | 78,450.00 |
| May 31, 2025 | -55,251.00 |
| Feb 28, 2025 | -43,354.00 |
| Nov 30, 2024 | -71,445.00 |
| Aug 31, 2024 | 297,212.00 |
| May 31, 2024 | 79,110.00 |
| Feb 29, 2024 | 577,256.00 |
| Nov 30, 2023 | 51,403.00 |
| Aug 31, 2023 | -421,671.00 |
| May 31, 2023 | -102,880.00 |
| Feb 28, 2023 | -203,260.00 |
| Nov 30, 2022 | 741,306.00 |
| Aug 31, 2022 | 252,669.00 |
| May 31, 2022 | -70,268.00 |
| Feb 28, 2022 | -383,506.00 |
| Nov 30, 2021 | -843,440.00 |
| Aug 31, 2021 | -258,613.00 |
| May 31, 2021 | 127,394.00 |
| Feb 28, 2021 | 167,552.00 |